Prurigo Nodularis - Market Insights, Epidemiology and Market Forecast to 2027 - ResearchAndMarkets.com
The "Prurigo Nodularis - Market Insights, Epidemiology and Market Forecast" drug pipelines has been added to ResearchAndMarkets.com's offering.
According to the report, the total prevalent cases of Prurigo Nodularis was 686,375 in 2016 in 7MM and, is expected to increase during the study period i.e., 2016-2027. Among 7MM, United States accounts for highest prevalent cases of Prurigo Nodularis with 256,941 prevalent cases in 2016.
Epidemiology: The Prurigo Nodularis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
Drug Chapters: This segment of the report encloses the detailed analysis of emerging drugs along with a key cross competition. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Market Outlook: This section of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
Drugs Uptake: This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027.
- Celgene Maruho
- Menlo Therapeutics
- Trevi Therapeutics
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bcxjg4/prurigo_nodularis?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181205005805/en/